Royalty Pharma reported a third-quarter beat and raise. Last year it looked at 480 opportunities and did about seven deals for $4.7 billion in announced transaction value. Its publicly stated goal is $2 to $2.5 billion a year in capital deployment, and management said those figures will go up over time as big pharma co-funding deals grow.
RPRX · Royalty Pharma plc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Royalty Pharma raised 2026 portfolio receipts guidance to $3.5 billion to $3.55 billion from $3.4 billion to $3.5 billion, citing 10% to 11% royalty-receipt growth expected versus 7% to 10% previously.
Royalty Pharma plc reported first-nine-month income from financial royalty assets of $1,880,627 thousand in 2026, up 12.7%, as net income attributable to the company fell 17.7% to $457,248 thousand.
Royalty Pharma plc reported third-quarter Portfolio Receipts of $890 million, up 9%, and raised full-year 2026 Portfolio Receipts guidance to $3,500 million to $3,550 million from $3,400 million to $3,500 million.
Royalty Pharma targets $2 to $2.5 billion in annual capital deployment, sees AI enhancing diligence, and is building a China investment team focused on passive royalties; leverage above 4 would require a compelling transaction and rapid deleveraging.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Royalty Pharma raised full-year guidance after 9% growth in quarterly Royalty and Portfolio Receipts, added three royalties and reported positive clinical and regulatory progress. Risks include the pelacarsen and Niktimvo trial failures, a $150 million pelacarsen impairment, declining Promacta and Imbruvica receipts, lower operating cash flow and net income, and reduced milestone receipts.
- + Royalty Pharma acquired royalty interests in Zoryve, Mimrylo and cliramitug during the third quarter.
- + Royalty Pharma announced $1 billion of R&D co-funding deals during 2026 and described additional opportunities in the deal funnel.
- + Royalty Pharma raised full-year 2026 Portfolio Receipts guidance to $3,500 million–$3,550 million and expects 10%–11% Royalty Receipts growth.
- + Royalty Pharma reported multiple positive clinical and regulatory developments across its royalty portfolio.
- − The pelacarsen Phase 3 trial missed its primary endpoint, and Royalty Pharma recorded a $150 million non-cash impairment.
- − Niktimvo failed to meet the primary endpoint of its Phase 2 MAXPIRe trial in idiopathic pulmonary fibrosis, and Syndax will not advance it in that indication.
- − Net cash provided by operating activities declined 2%, to $686 million from $703 million.
- − Milestones and other contractual receipts are expected to decrease to approximately $65 million in 2026 from $128 million in 2025.
- − Promacta and Imbruvica receipts declined, partly offsetting growth from Tremfya, Voranigo, Evrysdi and Imdelltra.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (non-GAAP) non-GAAP | $736M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Portfolio Receipts $773M
-$37M Payments for operating and professional costs
= Adjusted EBITDA (non-GAAP) $736M
|
|||
| Capital Deployment | $349M | Q2 2026 | — |
| Portfolio Cash Flow (non-GAAP) non-GAAP | $736M | Q2 2026 | — |
| Portfolio Receipts | $772.98M | the three months ended June 30, 2026 filing | — |
| Weighted average Class A ordinary shares outstanding - diluted | 557M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RPRX
this stock
Royalty Pharma plc
|
$39.40B | +77.7% | +5.1% | 44.9 | 2.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$135.44B | +17.8% | +46.2% | 34.4 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$99.08B | +24.1% | +20.8% | 21.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.68B | +601.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$64.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 22
Royalty Pharma reported a third-quarter beat and raise. Last year it looked at 480 opportunities and did about seven deals for $4.7 billion in announced transaction value. Its publicly stated goal is $2 to $2.5 billion a year in capital deployment, and management said those figures will go up over time as big pharma co-funding deals grow.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RPRX | -1.1% | +10.3% | +26.1% | +2.2% | +77.7% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +1.2% | +15.1% | +29.0% | +5.3% | +70.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.